We regularly have new studies that we are recruiting for. If you don’t see something that you qualify for right now, please call Caitlin at 952-993-9605 to be contacted about future studies.
Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People with T2 Diabetes (FLASH)
Principal Investigator: Thomas Martens, MD
Study Sponsor: Abbott Diabetes Care
Location: International Diabetes Center
Purpose of study: The goal of this study is to decrease the amount of time that a person with type 2 diabetes spends with blood glucose in high ranges through the use of a continuous glucose monitoring (CGM) system. The study will help participants focus on changing their food choices and other behaviors that can have an effect on glucose. All participants in the study will be provided with the FreeStyle Libre CGM system. This CGM system is FDA approved and currently available for use. It has a sensor that measures a person’s glucose level continuously. Participants in this study will either use the FreeStyle Libre CGM system alone, or in combination with a new smartphone app that is used to log and understand the effect of foods on glucose.
Inclusion Criteria: The study is accepting males and females ages 18 and older who:
-Have type 2 diabetes
-Are taking 1 or 2 medications (non-insulin) to treat their diabetes
-Have an AIC between 7.5-9.5%
-Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
Multi-center, Randomized, Parallel, Adaptive, Controlled Trial in Adult and Pediatric Patients with Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home (Medtronic 304)
Principle Investigator: Anders Carlson, MD
Study Sponsor: Medtronic Minimed
Location: International Diabetes Center
Purpose of Study: The purpose of this study is to look at the safety and effectiveness of the hybrid closed loop (HCL) insulin pump system, MiniMed 770G, used in a home setting by people with type 1 diabetes. This system consists of an insulin pump, a Medtronic glucose sensor, an insertion device for the sensor, a transmitter and a glucose meter. The HCL uses continuous glucose sensor information to tell the insulin pump how much insulin to infuse automatically to help control glucose levels in people who have type 1 diabetes. The MiniMed 770G has been approved by the FDA for use in the United States for ages 2 and older. Study participants will be randomly assigned so that about half will use the insulin pump in the HCL mode. The other half will either continue with multiple daily injections, if that is what they are currently using, or use the MiniMed 770G either with CGM (but without HCL mode) depending on their pre-study therapy. After about 6 months, all participants will use the insulin pump in the HCL mode using the continuous glucose monitor sensor.
Inclusion Criteria:
– 65-80 years old
– Have had type 1 diabetes for 3 months or longer
– Take insulin injections or use an insulin pump
– Are willing to use Humalog or Novolog insulin throughout the study
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@ParkNicollet.com
Weight Loss Wizard: Patient Perspective Interviews (Weight Loss Wizard)
Principal Investigator: Patrick O’Connor, MD, MPH, MA
Study sponsor: NIH/NIDDK
Location: Enrolled participants do not need to travel
Purpose of study: The Weight Loss Wizard participant interview is supported by National Institutes of Health to gather input from patients about their experiences with talking to their primary care doctors about weight loss options. The information gathered will help guide design and content of a shared decision-making tool used at the point of care. The interview is being offered via phone or conference call to patients with Type 2 Diabetes.
Inclusion Criteria:
-Patients with Type 2 Diabetes
Exclusion Criteria:
-Previous metabolic bariatric surgery
Study Contact:
Center for Evaluation and Survey Research
(952) 967-6912
WeightLossWizard@HealthPartners.com
